News Search Results
Mar 13, 2026, 10:17 ET Water Soluble Fertilizer Market size to Reach USD 28.6 Billion by 2032, Shows Maximize Market Research Analysis
Iperen International (Netherlands)21. J.R. Simplot Company (USA)22. ICL Fertilizers (Israel)23. ADOB (Agricultural and Food Biotechnology) (Poland)24. Artal Agronutrientes (Spain)25. Astra Chemicals (Saudi Arabia)Get access to the full description of the report
More news about: Maximize Market Research Pvt. Ltd.
Mar 13, 2026, 09:59 ET Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial results
More news about: Insilico Medicine
Mar 13, 2026, 08:06 ET Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy
deliver safer and more effective breakthrough treatment options for patients worldwide!About UniXell BiotechShanghai UniXell Biotechnology Co., Ltd. was established in 2021, specializing in the research and development of cell therapy drugs for neurological diseases, including Parkinson's
More news about: Unixell Biotech
Mar 13, 2026, 05:14 ET Aphranel figure sur la liste Forbes China Beauty 100
13 mars 2026 /PRNewswire/ -- Aphranel, une marque d'esthétique médicale régénérative d'origine chinoise de la société SHANGHAI MOYANG BIOTECHNOLOGY, a été nommée dans la troisième liste Forbes China Beauty 100, publiée par Forbes China, qui reconnaît les marques du secteur de la beauté et de
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Mar 13, 2026, 02:50 ET Aphranel wird in die Forbes China Beauty 100 Liste aufgenommen
2026 /PRNewswire/ -- Aphranel, eine aus China stammende Marke für regenerative medizinische Ästhetik unter dem Unternehmen SHANGHAI MOYANG BIOTECHNOLOGY, wurde in die dritte Forbes China Beauty 100-Liste aufgenommen, die von Forbes China veröffentlicht wird und Marken in Chinas Schönheits- und medizinischer
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Mar 12, 2026, 23:54 ET Aphranel Named to Forbes China Beauty 100 List
March 13, 2026 /PRNewswire/ -- Aphranel, a China-origin regenerative medical aesthetics brand under the company SHANGHAI MOYANG BIOTECHNOLOGY, has been named to the Third Forbes China Beauty 100 list, published by Forbes China, which recognizes brands in China's beauty and medical aesthetics
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Mar 12, 2026, 23:23 ET Aphranel Named to Forbes China Beauty 100 List
2026 /PRNewswire/ -- Aphranel, a China-origin regenerative medical aesthetics brand under the company SHANGHAI MOYANG BIOTECHNOLOGY, has been named to the Third Forbes China Beauty 100 list, published by Forbes China, which recognizes brands in China's beauty and medical aesthetics
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Mar 12, 2026, 20:00 ET PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement
https://www.receptor.ai/About PRISM BioLabPRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction
More news about: PRISM Biolab
Mar 12, 2026, 19:45 ET REJURAN COSMETICS Debuts at Sephora, Expanding Its Footprint Across the U.S. Market
March 12, 2026 /PRNewswire/ -- REJURAN COSMETICS, No.1 medical aesthetic brand developed by global pharmaceutical biotechnology company PharmaResearch, recently announced its official launch at Sephora, marking a major milestone in the brand's North American expansion. The
More news about: REJURAN COSMETICS
Mar 12, 2026, 16:27 ET Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that
More news about: Curis, Inc.
Mar 12, 2026, 16:15 ET Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
information and a PIN allowing them to access the live call. About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Mar 12, 2026, 16:05 ET INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
PLYMOUTH MEETING, Pa., March 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 12, 2026, 14:42 ET Micro Electrode Array Market to Reach USD 1,991.35 Million by 2032 Amid Rising Neuroscience Research, iPSC-Based Disease Modeling, and High-Density Electrophysiology Adoption - Credence Research
Drug Discovery, Tissue Engineering, and Others.By End-user, the market includes Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Hospitals & Clinical Laboratories, and Others.By Material, the market includes Glass, Polymer,
More news about: Credence Research Inc.
Mar 12, 2026, 11:45 ET Rosalind Franklin University Doubles Helix 51 Incubator
today announced the expansion of its Helix 51 biomedical incubator, doubling its available space in response to growing demand from early-stage biotechnology companies seeking laboratory and commercialization support.
More news about: Rosalind Franklin University of Medicine and Science
Mar 12, 2026, 10:38 ET Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, is featured on today's Water
More news about: Anixa Biosciences, Inc.
Mar 12, 2026, 10:00 ET Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis
MISSOULA, Mont., March 12, 2026 /PRNewswire/ -- Inimmune Corporation, a clinical-stage biotechnology company developing novel immunotherapies for allergic diseases, today announced the completion of enrollment and dosing of the first patient in
More news about: Inimmune
Mar 12, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Mar 12, 2026, 09:05 ET BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Patient Information.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Mar 12, 2026, 09:01 ET MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
CAMBRIDGE, Mass., March 12, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a comprehensive global intellectual property portfolio supporting vanoglipel
More news about: MetaVia Inc.
Mar 12, 2026, 09:00 ET Aminex Therapeutics Receives Second FDA Orphan Drug Designation for AMXT 1501 for Malignant Glioma Including DIPG - a Highly Aggressive Childhood Brain Cancer
SEATTLE, March 12, 2026 /PRNewswire/ -- Aminex Therapeutics, Inc., a clinical-stage biotechnology company focused on developing a novel metabolic-targeted therapy to treat adult and pediatric cancers, today announced that the U.S. Food and Drug
More news about: Aminex Therapeutics, Inc.
Mar 12, 2026, 09:00 ET Kenai Therapeutics Appoints Allen Waldrop to Board of Directors
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the appointment of Allen Waldrop to the company's
More news about: Kenai Therapeutics/BIOCOM
Mar 12, 2026, 09:00 ET Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson's Disease
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced that the World Health Organization (WHO) has published Sasineprocel as the
More news about: Aspen Neuroscience, Inc.
Mar 12, 2026, 09:00 ET K18 LAUNCHES TRIPLEBRIGHT™ - THE NEXT GENERATION OF PURPLE SHAMPOO DELIVERING BLONDE LIKE NEW
mission is to liberate the freedom of self expression through healthy hair. Its patented K18PEPTIDE™, is a breakthrough ingredient developed from biotechnology that is revolutionizing the industry. Unlike traditional treatments, the K18PEPTIDE™ works at the molecular level, mimicking the natural structure
More news about: K18 Biomimetic Hairscience
Mar 12, 2026, 08:30 ET Cresilon Announces Poster Presentation on TRAUMAGEL Case Study at the 2026 Advanced Trauma Life Support Global Symposium
NEW YORK, March 12, 2026 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that a retrospective clinical case series demonstrating the use of TRAUMAGEL®,
More news about: Cresilon
Mar 12, 2026, 08:30 ET Halozyme Appoints David Ramsay as Interim Chief Financial Officer
company continues its active search for a permanent CFO.Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale‑up. He
More news about: Halozyme Therapeutics, Inc.